What evidence was found on the cost effectiveness of NP monitoring for patients with HFREF under the age of 75?
The committee noted the variety of monitoring protocols used in the RCTs, and raised some concern about the potential range in cost of the intervention depending on the frequency of monitoring. The most recent cost-effectiveness analysis assumed NP testing every 3 months, but that this would cease after 18 months. Based on this, the committee agreed that NP monitoring is likely to be cost effective for HFREF patients under the age of 75.